Table 4.
Kaplan-Meier estimates for time to relapse following a rise in PR3-ANCA*
| Direct ELISA
|
|||||
|---|---|---|---|---|---|
| Median time to relapse | Cumulative Relapse, % (95% C.I.)
|
||||
| N | 6 months | 12 months | 18 months | ||
| All subjects with rise in PR3-ANCA | |||||
| Any relapse | 52 | 11.8 mo. | 33 (19, 45) | 50 (33, 63) | 60 (43, 72) |
| Severe relapse | 60 | 19.1 mo. | 27 (15, 38) | 43 (29, 55) | 49 (34, 61) |
| Renal involvement at enrollment | |||||
| Any relapse | 31 | 19.1 mo. | 30 (12, 45) | 46 (24, 61) | 46 (24, 61) |
| Severe relapse | 37 | 22.5 mo. | 25 (9, 38) | 40 (21, 55) | 44 (24, 59) |
| Alveolar hemorrhage at enrollment | |||||
| Any relapse | 15 | 5.2 mo. | 53 (20, 73) | 69 (32, 86) | 77 (39, 91) |
| Severe relapse | 17 | 8.5 mo. | 41 (12, 60) | 61 (28, 79) | 67 (34, 84) |
| Rituximab | |||||
| Any relapse | 27 | 11.5 mo. | 35 (14, 51) | 57 (32, 63) | 65 (40, 80) |
| Severe relapse | 34 | 11.8 mo. | 30 (13, 45) | 50 (29, 65) | 57 (36, 71) |
| Cyclophosphamide | |||||
| Any relapse | 25 | 17.2 mo. | 32 (11, 48) | 44 (21, 61) | 54 (29, 71) |
| Severe relapse | 26 | 22.5 mo. | 23 (5, 38) | 35 (14, 51) | 40 (17, 56) |
*
Analyses include only individuals who experienced a rise in PR3-ANCA during follow-up while at risk for the specified type of relapse; rises detected concurrent with the specified type of relapse were treated as if no rise had occurred. Time zero corresponds to the date of the rise in PR3-ANCA level. The number of patients with a rise before “severe relapse” is higher than that before “any relapse” because for each grouping, one or more patients experienced a rise in PR3-ANCA level concurrent with or after a non-severe relapse, while still “at risk” for (before the occurrence of) a severe relapse.